Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free ONS Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Oncobiologics (ONS) Competitors

Oncobiologics logo
Compare

ONS vs. IZTC, ALVR, ZIVO, FNCH, and NKGN

Should you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Invizyne Technologies (IZTC), AlloVir (ALVR), ZIVO Bioscience (ZIVO), Finch Therapeutics Group (FNCH), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector.

How does Oncobiologics compare to Invizyne Technologies?

Oncobiologics (NASDAQ:ONS) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Invizyne Technologies has lower revenue, but higher earnings than Oncobiologics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncobiologics$3.81M4.74-$38.84MN/AN/A
Invizyne TechnologiesN/AN/AN/AN/AN/A

Invizyne Technologies has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%.

Company Net Margins Return on Equity Return on Assets
Oncobiologics-464.47% N/A -93.28%
Invizyne Technologies N/A N/A N/A

In the previous week, Invizyne Technologies had 1 more articles in the media than Oncobiologics. MarketBeat recorded 1 mentions for Invizyne Technologies and 0 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score.

Company Overall Sentiment
Oncobiologics Neutral
Invizyne Technologies Neutral

7.2% of Oncobiologics shares are held by institutional investors. 11.5% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Oncobiologics and Invizyne Technologies tied by winning 3 of the 6 factors compared between the two stocks.

How does Oncobiologics compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Oncobiologics (NASDAQ:ONS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Oncobiologics has higher revenue and earnings than AlloVir.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlloVirN/AN/A-$190.42M-$20.23N/A
Oncobiologics$3.81M4.74-$38.84MN/AN/A

AlloVir has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%. Oncobiologics' return on equity of 0.00% beat AlloVir's return on equity.

Company Net Margins Return on Equity Return on Assets
AlloVirN/A -71.03% -61.27%
Oncobiologics -464.47%N/A -93.28%

66.1% of AlloVir shares are held by institutional investors. Comparatively, 7.2% of Oncobiologics shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 11.5% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500.

In the previous week, AlloVir's average media sentiment score of 0.00 equaled Oncobiologics'average media sentiment score.

Company Overall Sentiment
AlloVir Neutral
Oncobiologics Neutral

Summary

AlloVir beats Oncobiologics on 5 of the 8 factors compared between the two stocks.

How does Oncobiologics compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Oncobiologics (NASDAQ:ONS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 7.2% of Oncobiologics shares are held by institutional investors. 48.9% of ZIVO Bioscience shares are held by company insiders. Comparatively, 11.5% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, ZIVO Bioscience's average media sentiment score of 0.00 equaled Oncobiologics'average media sentiment score.

Company Overall Sentiment
ZIVO Bioscience Neutral
Oncobiologics Neutral

ZIVO Bioscience has higher earnings, but lower revenue than Oncobiologics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZIVO Bioscience$15.85K1,073.09-$7.78M-$2.18N/A
Oncobiologics$3.81M4.74-$38.84MN/AN/A

ZIVO Bioscience has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%.

Company Net Margins Return on Equity Return on Assets
ZIVO BioscienceN/A N/A -2,240.92%
Oncobiologics -464.47%N/A -93.28%

ZIVO Bioscience has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500.

Summary

ZIVO Bioscience beats Oncobiologics on 6 of the 8 factors compared between the two stocks.

How does Oncobiologics compare to Finch Therapeutics Group?

Oncobiologics (NASDAQ:ONS) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

7.2% of Oncobiologics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 11.5% of Oncobiologics shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Finch Therapeutics Group has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%. Oncobiologics' return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Oncobiologics-464.47% N/A -93.28%
Finch Therapeutics Group N/A -69.14%-26.92%

Oncobiologics has a beta of -0.27, indicating that its stock price is 127% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

In the previous week, Oncobiologics' average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.

Company Overall Sentiment
Oncobiologics Neutral
Finch Therapeutics Group Neutral

Oncobiologics has higher revenue and earnings than Finch Therapeutics Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncobiologics$3.81M4.74-$38.84MN/AN/A
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A

Summary

Finch Therapeutics Group beats Oncobiologics on 5 of the 8 factors compared between the two stocks.

How does Oncobiologics compare to NKGen Biotech?

NKGen Biotech (NYSE:NKGN) and Oncobiologics (NASDAQ:ONS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 7.2% of Oncobiologics shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 11.5% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NKGen Biotech has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Oncobiologics -464.47%N/A -93.28%

NKGen Biotech has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500.

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Oncobiologics'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Oncobiologics Neutral

Oncobiologics has higher revenue and earnings than NKGen Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.51N/A
Oncobiologics$3.81M4.74-$38.84MN/AN/A

Summary

Oncobiologics beats NKGen Biotech on 4 of the 7 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONS vs. The Competition

Export
MetricOncobiologicsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$18.06M$329.01M$6.25B$11.76B
Dividend YieldN/AN/A2.74%5.26%
P/E RatioN/AN/A29.2527.07
Price / Sales4.74189.48504.6973.43
Price / CashN/A22.4443.3053.90
Price / Book-0.184.739.676.69
Net Income-$38.84M-$132.96M$3.55B$332.64M

Oncobiologics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONS
Oncobiologics
N/A$0.25
+17.4%		N/A-83.9%$18.06M$3.81MN/AN/A
IZTC
Invizyne Technologies
N/A$9.75
-2.3%		N/A-10.5%$60.96MN/AN/A29
ALVR
AlloVir
N/A$5.46
-1.1%		N/A-5.1%$27.54MN/AN/A110
ZIVO
ZIVO Bioscience
N/A$3.55
-6.6%		N/A-69.2%$14.21M$15.85KN/A10
FNCH
Finch Therapeutics Group
N/A$8.15
+12.7%		N/A-35.1%$13.09MN/AN/A190

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ONS) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Did you miss The Dark AI Summit?
Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...
Brownstone Research | Sponsoredtc pixel
Why Elon just bought a power plant (Ticker inside)
Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer witho...
Behind the Markets | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel